Question: Will I be able to get safely treated for HIV during the coronavirus outbreak?

Answer passage (source: WHO):
page_title: Q&A: HIV, antiretrovirals and COVID-19
section_headers: How can programmes assure continued access to HIV services?
section_content: It is important to assure continuous access to essential HIV prevention,
testing and treatment services also where measurements of confinement are
implemented within the public health response to the COVID-19 pandemic. While
access to essential services should be maintained, adapted and evidence-based
measures to reduce possible transmission should be considered and implemented.
These include[12]:

Applying standard precautions for all patients (including ensuring that all patients cover their nose and mouth with a tissue or elbow when coughing or sneezing, offering a medical mask to patients with suspected COVID-19 infection while they are in waiting in the service, perform hand hygiene etc.) 
Health care and outreach workers, as well as peer educators and clients should apply adapted hand hygiene measures
Ensuring triage, early recognition, and source control (isolating patients with suspected COVID-19 infection)
Ensure there is adequate ventilation in all areas in the healthcare facility
Spatial separation of at least 1 metre should ideally be maintained between all patients within all types of services
Cleaning and disinfection procedures should be followed consistently and correctly
Dispensing medicines (for treatment of HIV, TB and other chronic conditions such as opioid dependence) for longer periods allowing reduced frequency of patient visits 
Consider reduction of services to the most critical ones (provision of essential treatment and prevention services; services such as counselling sessions may be reduced or adapted)

Generally, vulnerable populations, including members of key populations, as
well as homeless and/or displaced people may be at increased risk of infection
– because of additional comorbidities impacting on their immune system,
reduced ability to apply measures of confinement and social distancing, as
well as generally limited access to health services. It is critical that
services that reach these populations such as community-based services, drop-
in centres and outreach services can continue providing life-saving prevention
(distribution of condoms, needles and syringes), testing and treatment while
securing safety of staff and clients. Services can be adapted according to
above considerations where applicable.

Reviewer feedback on this answer:
Is clear that everyone with HIV should still have access to treatment during the coronavirus epidemic.
It thoroughly answers the question. It offers multiple pieces of advice.

Reviewer ratings:
Excellent
Excellent

Answer passage (source: WHO):
page_title: Q&A: HIV, antiretrovirals and COVID-19
section_headers: Are people living with HIV at increased risk of being infected with the virus that causes COVID-19?
section_content: People living with HIV with advanced disease, those with low CD4 and high
viral load and those who are not taking antiretroviral treatment have an
increased risk of infections and related complications in general. It is
unknown if the immunosuppression of HIV will put a person at greater risk for
COVID-19, thus, until more is known, additional precautions for all people
with advanced HIV or poorly controlled HIV, should be employed[1],[2]. __
At present there is no evidence that the risk of infection or complications of
COVID-19 is different among people living with HIV who are clinically and
immunologically stable on antiretroviral treatment when compared with the
general population. Some people living with HIV may have known risk factors
for COVID-19 complications, such as diabetes, hypertension and other
noncommunicable diseases and as such may have increased risk of COVID-19
unrelated to HIV. We know that during the SARS and MERS outbreaks there were
only a few case reports of mild disease among people living with HIV.
To date, there is a case report of a person living with HIV who had COVID-19
and recovered[3] and a small study on risk factors and antiretrovirals used
among people living with HIV with COVID-19 from China. This study reported
similar rates of COVID-19 disease as compared to the entire population and
increased risk with older age, but not with low CD4, high viral load level or
antiretroviral regimen[4]. Current clinical data suggest the main mortality
risk factors are linked to older age and other comorbidities including
cardiovascular disease, diabetes, chronic respiratory disease, and
hypertension. Some very healthy people have also developed severe disease from
the coronavirus infection[5].
PLHIV are advised to take the same precautions as the general
population[6],[7]:


wash hands often


cough etiquette 


physical distancing


seek medical care if symptomatic


self-isolation if in contact with someone with COVID-19 and 


other actions per the government response 


People living with HIV who are taking antiretroviral drugs should ensure that
they have at least 30 days and up to 6-month supply of medicines and ensure
that their vaccinations are up to date (influenza and pneumococcal vaccines).
Adequate supplies of medicines to treat co-infections and comorbidities and
addiction should also be ensured.

Reviewer feedback on this answer:
Final paragraph clearly states that people with HIV should continue with their treatment.
The answer is about how at risk people with HIV are at getting the coronavirus. The question is mostly about getting help for HIV.

Reviewer ratings:
Excellent
Bad

Answer passage (source: WHO):
page_title: Q&A: HIV, antiretrovirals and COVID-19
section_headers: Can antiretrovirals be used to treat COVID-19?
section_content: Several studies have suggested that patients infected with the virus causing
COVID-19, and the related coronavirus infections (SARS-CoV and MERS-CoV) had
good clinical outcomes, with almost all cases recovering fully. In some cases,
patients were given an antiretroviral drug: lopinavir boosted with ritonavir
(LPV/r). These studies were mostly carried out in HIV-negative individuals.
It is important to note that these studies using LPV/r had important
limitations. The studies were small, timing, duration and dosing for treatment
were varied and most patients received co-interventions/co-treatments which
may have contributed to the reported outcomes.
While the evidence of benefit of using antiretrovirals to treat coronavirus
infections is of very low certainty, serious side effects were rare. Among
people living with HIV, the routine use of LPV/r as treatment for HIV is
associated with several side effects of moderate severity. However, as the
duration of treatment in patients with coronavirus infections was generally
limited to a few weeks, these occurrences can be expected to be low or less
than that reported from routine use.

Reviewer feedback on this answer:
Tangentially addresses HIV treatment, in the context of HIV drugs being effective against coronavirus, but doesn't directly say whether HIV+ individuals will have reliable access to treatment.
The answer is about HIV-negative people getting treated for the coronavirus. It's not about getting treated for HIV.

Reviewer ratings:
Could be Improved
Bad